[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553527":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":66,"collaborators":69,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":18,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":18,"enrollmentInfo":82,"targetDuration":18,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":96,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Access to home blood transfusions while enrolled in hospice (HEME-Hospice care)","EXPERIMENTAL","Participants assigned to access to HEME-Hospice care who enroll in hospice will have at least once weekly assessment of symptoms of anemia and thrombocytopenia by the study team and will receive transfusions at home as indicated. Individualized care appointments with hospice care team providers, and frequency of visits are determined by individual participant need.",[13],"Behavioral: HEME-Hospice Program",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm 2: Usual Care","NO_INTERVENTION","Participants assigned to usual care will receive standard oncology care delivered by the hematologic oncologists. Participants will have access to regular\u002Fstandard hospice care if they elect to enroll in hospice.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","HEME-Hospice Program","A care delivery program that combines home-based transfusions with routine home hospice care. Transfusions are administered by trained transfusion nurses. Standard hospice care is provided by an interdisciplinary team of non-transfusion nurse case managers, hospice aides, social workers, and chaplains.",[9],[26],"HEME-Hospice",[28],{"name":29,"affiliation":5,"role":30},"Oreofe Odejide, MD, MPH","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","617-632-6864","Oreofe_Odejide@dfci.harvard.edu",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Sunny Rosenthal, MPH","857-215-2820","sjrosenthal@mgb.org",[41,58],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Brigham and Women's Hospital","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-71.05977,42.35843,{"lat":53,"lon":52},[56,57],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},{"name":29,"role":30,"phone":18,"phoneExt":18,"email":18},{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},{"type":50,"coordinates":60},[52,53],{"lat":53,"lon":52},[63,64],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},{"name":65,"role":30,"phone":18,"phoneExt":18,"email":18},"Oreofe O. Odejide, MD",{"type":30,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Oreofe Odejide, MD","Principal Investigator",[70],{"name":71,"class":72},"National Cancer Institute (NCI)","NIH","100553527","heme-home-transfusion-program-100553527",false,"NCT06487247","HEME Home Transfusion Program","Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial","Inclusion Criteria for Patient Participants:\n\n* Diagnosis of a relapsed\u002Frefractory hematologic malignancy\n* Age ≥ 18 years\n* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)\n* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction\n* Patient resides within catchment served by Care Dimensions Hospice\n* Physician-estimated prognosis of six months or less\n\nInclusion Criteria for Caregivers:\n\n* Identified informal caregiver of enrolled patient with hematologic malignancy\n* Age ≥ 18 years\n\nExclusion Criteria for Patient Participants:\n\n* Age \\\u003C 18 years\n* Already enrolled in hospice\n* Resides in nursing home or assisted living facility\n* History of previous serious adverse transfusion reaction\n\nExclusion Criteria for Caregivers:\n\n-Age \\\u003C 18 years","ALL","18 Years",{"count":83,"type":84},700,"ESTIMATED","INTERVENTIONAL",[87],"NA","This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.",[90,91,92,93,94,95],"Leukemia","Myeloma","Myelodysplastic Syndromes","Hematologic Malignancy","Hematologic Diseases","Lymphoma",[90,91,92,93,94,95],"2025-09-15",{"date":99,"type":100},"2025-09-17","ACTUAL",{"date":102,"type":100},"2025-09-10",{"date":104,"type":84},"2029-05-31",{"name":5,"class":6},2]